Selective PI3Kδ Inhibitors for Respiratory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3-kinase inhibitors lack specificity, particularly for PI3Kδ, and are not effective in treating a wide range of disorders mediated by inappropriate PI3-kinase activity, including respiratory diseases, autoimmune diseases, and cancers, due to their non-selective inhibition of Class I PI3-kinases.
Innovation Solution
Development of novel compounds, such as those of formula (I), which are selective inhibitors of PI3-kinase activity, particularly targeting PI3Kδ, to treat disorders associated with inappropriate PI3-kinase activity, including asthma, COPD, and autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective PI3-kinase inhibitors are used, then PI3-kinase activity is inhibited, but specificity for PI3Kδ is lost
Solution Approach 1:
The compound is designed with specific structural features (R1 as 9- or 10-membered bicyclic heteroaryl, R2 as pyridinyl with specific substituents) that create local interactions with the PI3Kδ binding pocket, enhancing selectivity for this specific isoform while maintaining inhibition effectiveness
Solution Approach 2:
The patent optimizes specific molecular parameters including the size and composition of the bicyclic heteroaryl ring (R1), the substitution pattern on the pyridinyl ring (R2), and the linker structure (R3, R4) to achieve the optimal balance between binding affinity and selectivity for PI3Kδ
2Adaptability or versatility
If broad-spectrum PI3-kinase inhibition is achieved, then multiple disorders can be treated, but off-target effects increase
Solution Approach 1:
The invention targets a specific segment (PI3Kδ) within the broader PI3-kinase family, using selective inhibition of this particular isoform to treat multiple disorders while avoiding off-target effects on other PI3-kinase isoforms that perform different physiological functions
3Measurement precision
If selective PI3Kδ inhibition is achieved, then therapeutic specificity is improved, but compound complexity increases
Solution Approach 1:
The compound combines multiple structural elements (bicyclic heteroaryl, pyridinyl ring, linker) into a composite molecular structure where each component contributes to the overall selectivity and binding affinity, achieving high specificity through the synergistic effect of these composite features
Data Source
AI summary
The invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.